Cargando…
Beyond a single pathway: combination therapy in pulmonary arterial hypertension
There is a strong rationale for combining therapies to simultaneously target three of the key pathways implicated in the pathogenesis of pulmonary arterial hypertension (PAH). Evidence to support this strategy is growing, and a number of studies have demonstrated that combination therapy, administer...
Autores principales: | Sitbon, Olivier, Gaine, Sean |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487558/ https://www.ncbi.nlm.nih.gov/pubmed/27903663 http://dx.doi.org/10.1183/16000617.0085-2016 |
Ejemplares similares
-
New trends in pulmonary hypertension
por: Cullivan, Sarah, et al.
Publicado: (2023) -
Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015) -
Diagnosis and management of pulmonary arterial hypertension
por: Cullivan, Sarah, et al.
Publicado: (2022) -
Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017) -
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)